Skip to main content
Inhibrx Biosciences, Inc. logo

Inhibrx Biosciences, Inc. — Investor Relations & Filings

Ticker · INBX ISIN · US45720N1037 US Manufacturing
Open in API
Filings indexed 119 across all filing types
Latest filing 2026-06-03 Declaration of Voting R…
Country US United States of America
Listing US INBX

About Inhibrx Biosciences, Inc.

https://inhibrx.com/

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel biologic therapeutics for patients with life-threatening conditions. The company leverages its expertise in protein engineering and an understanding of target biology to advance a pipeline of therapeutic candidates. Its clinical programs are focused on oncology, with lead trials covering cancers such as sarcoma, chondrosarcoma, and head and neck cancer. A key candidate in its pipeline is ozekibart (INBRX-109), a tetravalent DR5 agonist. Inhibrx combines deep scientific and clinical experience with an agile and innovative approach to address unmet medical needs in biotherapeutics.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 96% confidence The document is a Form 8-K current report with Item 5.07 “Submission of Matters to a Vote of Security Holders,” which provides detailed voting results for proposals at the Annual Meeting. This corresponds to an official declaration of voting results. Therefore, it should be classified as Declaration of Voting Results & Voting Rights Announcements (Code: DVA).
2026-06-03 English
8-K
Regulatory Filings Classification · 87% confidence The document is a Form 8-K “Current Report” under the Exchange Act, specifically reporting Item 2.02 “Results of Operations and Financial Condition” by furnishing a press release as Exhibit 99.1. It does not itself contain detailed financial statements nor is it the press release text, and it is a regulatory compliance filing rather than the full report (10-K/IR), an earnings release, or other specialized category. Therefore, it falls into the fallback Regulatory Filings category.
2026-05-14 English
10-Q
Interim / Quarterly Report Q1 2026
2026-05-14 English
8-K - Inhibrx Biosciences, Inc. (0002007919) (Filer)
Regulatory Filings Classification · 85% confidence The document is a U.S. SEC Form 8-K “Current Report” filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, covering Regulation FD disclosure (press release and investor presentation) and interim clinical trial updates. It is a general regulatory filing rather than a standalone financial report or other specialized category, so it falls into the Regulatory Filings fallback category (RNS).
2026-05-11 English
ARS - Inhibrx Biosciences, Inc. (0002007919) (Filer)
Annual Report
2026-04-23 English
DEF 14A - Inhibrx Biosciences, Inc. (0002007919) (Filer)
Proxy Solicitation & Information Statement
2026-04-23 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.